Literature DB >> 2900187

Prevention of pancreatic reactions by bolus somatostatin administration in patients undergoing endoscopic retrograde cholangio-pancreatography and endoscopic sphincterotomy.

J M Bordas1, V Toledo, F Mondelo, J Rodés.   

Abstract

Mild pancreatitis is a common complication of endoscopic retrograde cholangio-pancreatography (ERCP) and endoscopic sphincterotomy. Knowing that a bolus injection of natural somatostatin (SRIF) dramatically reduces pancreatic secretion, a study was conducted in 33 subjects undergoing invasive diagnostic procedures. A placebo (n = 16) or SRIF (n = 17; 4 micrograms/kg) were injected before cannulation. Enzymatic rise was observed in 16 (94%) subjects receiving placebo and in 8 (50%) injected previously with SRIF. In the former group 65% reported abdominal pain whereas only 19% had this complaint in the SRIF series. Results suggest that a bolus injection of SRIF may attenuate pancreatic irritation caused by diagnostic procedures or sphincterotomy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2900187     DOI: 10.1159/000180981

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  9 in total

Review 1.  Therapeutic potential of a long acting somatostatin analogue in gastrointestinal diseases.

Authors:  L J O'Donnell; M J Farthing
Journal:  Gut       Date:  1989-09       Impact factor: 23.059

2.  Effect of octreotide on human sphincter of Oddi motility following liver transplantation.

Authors:  F H Weber; R J Sears; B Kendall; T L Pruett; H A Shaffer; P Yeaton
Journal:  Dig Dis Sci       Date:  1997-06       Impact factor: 3.199

3.  A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis.

Authors:  W Uhl; M W Büchler; P Malfertheiner; H G Beger; G Adler; W Gaus
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

4.  Meta-analysis: somatostatin or its long-acting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis.

Authors:  Fumio Omata; Gautam Deshpande; Yasuharu Tokuda; Osamu Takahashi; Sachiko Ohde; David L Carr-Locke; Joshua L Jacobs; Tetsuya Mine; Tsuguya Fukui
Journal:  J Gastroenterol       Date:  2010-04-07       Impact factor: 7.527

Review 5.  Acute pancreatitis: nonsurgical management.

Authors:  S Tenner; P A Banks
Journal:  World J Surg       Date:  1997-02       Impact factor: 3.352

6.  Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis?

Authors:  K F Binmoeller; A G Harris; R Dumas; C Grimaldi; J P Delmont
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

7.  Beneficial effect of octreotide treatment in acute pancreatitis in rats.

Authors:  J Marton; Z Szasz; Z Nagy; K Jarmay; T Takacs; J Lonovics; A Balogh; G Farkas
Journal:  Int J Pancreatol       Date:  1998-12

Review 8.  Somatostatin and somatostatin analogues--are they indicated in the management of acute pancreatitis?

Authors:  C J McKay; C W Imrie; J N Baxter
Journal:  Gut       Date:  1993-11       Impact factor: 23.059

9.  Prophylactic effect of somatostatin in preventing Post-ERCP pancreatitis: an updated meta-analysis.

Authors:  Xie Qin; Wen S Lei; Zhang X Xing; Feng Shi
Journal:  Saudi J Gastroenterol       Date:  2015 Nov-Dec       Impact factor: 2.485

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.